Combination therapy with alendronate and alphacalcidol for prevention of symptomatic vertebral fracture in elderly patients treated with high-dose glucocorticoid: a multicenter open-label randomized controlled trial. - ALIS study

Society for glucocorticoid-induced osteoporosis0 个研究点目标入组 200 人开始时间: 2010年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patient who was not treated for more than 6 months (except, who had symptomatic vertebral fractures). 2)Patient who has serious renal disorder (EGFR: <35ml or Cre: more than 1.5mg/ml). 3)Patient who has a history of renal stone past 5 years. 4)Patient with primary or secondary hyperparathyroidism. 5)Patient with hyperthyroidism or hypothyroidism. 6)Patients who is diagnosed as contraindication of alendronate treatements or Alfacalcidol. 7)Patient who are treated with warfarin. 8)Patient who is inappropriate for this study by physician. 9)Patient who has experiences of receiving bisphosphonate treatment within 6 months at inclusion of the study. 10)Patient who has experiences of receiving drugs having influence on bone remodeling within 6 months at inclusion of the study (Estrogen, Vitamin D, Calcitonin, Raloxifene, Ipriflavone, Vitamin K, Steroid)

发起方

Society for glucocorticoid-induced osteoporosis